We are studying the safety and tolerability of eganelisib alone and with cytarabine in patients with relapsed or refractory acute myeloid leukemia. This trial aims to find the best dose and evaluate how well the treatment works.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed or refractory acute myeloid leukemia (AML) is a type of blood cancer that occurs when the disease returns after treatment or does not respond to initial therapy. It can lead to serious complications and requires specialized treatment.
Higher-risk myelodysplastic syndromes (HR-MDS) are a group of disorders caused by poorly formed or dysfunctional blood cells, leading to a higher risk of developing acute myeloid leukemia. Symptoms can include fatigue, infections, and bleeding issues.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.